Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04973007 · ClinicalTrials.gov registry record · Phase 4
Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases
A Phase 4 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT04973007 is a Phase 4 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 10 participants.
The verdict
NCT04973007, a Phase 4 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
If an abbreviated hepatobiliary phase (HBP) protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal cancer, its use will save time, cost, and patients' effort.
Interventions
- DRUG Gadoxetate disodium
- DRUG Gadobenate dimeglumine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2025-05-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04973007
The ClinicalTrials.gov registry entry for NCT04973007 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gadoxetate disodium is the first listed.
NCT04973007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04973007 about?
NCT04973007 is a clinical study titled "Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases". If an abbreviated hepatobiliary phase (HBP) protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal cancer, its use will save time, cost, and patients' effort.
What is the current status of trial NCT04973007?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2021-06-22. Estimated completion is 2025-05-08.
What interventions are being tested in trial NCT04973007?
The interventions under investigation include: Gadoxetate disodium (DRUG), Gadobenate dimeglumine (DRUG).
Who is sponsoring clinical trial NCT04973007?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.